NanoVibronix signs research agreement with University of Michigan for RCT of UroShield

ENvue Medical, Inc.

UroShield study targets nursing home residents; aims to reduce UTIs, catheter blockages, and pain.
Pilot of 20 patients precedes full study of over 300 patients; expected to start H1 2024.
Positive results could support application to FDA for permanent clearance; currently under Enforcement Discretion.
Study led by Center for Research and Innovations in Special Populations (CRIISP) at University of Michigan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.